Hemodialysis: slightly beyond basics Dialysate calcium and magnesium concentrations
|
|
- Godwin Walker
- 6 years ago
- Views:
Transcription
1 Dialysate calcium and magnesium concentrations Stefan Farese Department of Nephrology Bürgerspital Solothurn
2 Dialysate calcium and magnesium concentrations Do we know the optimal concentrations? NO Short overview Pathophysiologic considerations Guidelines/recommendations (if available) Personal suggestions (after review of the literature)
3 Dialysate calcium concentrations over time Evolution of dialysate Ca concentrations over time aluminium PB PTH suppression Calcitriol, Ca PB Adynamic bone disease Vascular calcification Recommandation without hard data 1.25 mmol/l 1.75 mmol/l mmol/l mmol/l 1.25 mmol/l 1960s 1970s 1980s, 1990s 2000 Messa P., NDT 2013 Toussaint et al. Hemodial Int 2006
4 Estimation of calcium balance in renal failure Vitamin D deficiency, phosphate binders dialysate Ca vascular calcification Hyper /Hypopara renal failure From Messa P. NDT 2013
5 Dialysate calcium concentrations hyperparathyreoidism increase Ca What is your goal? Treatment of... hypoparathyreoidism and adynamic bone disease hyper or hypocalciemia hemodynamic stability during dialysis decrease Ca decrease /increase Ca increase Ca hyperphosphatemia with calcium/noncalcium phosphate binders, calcitriol decrease /increase Ca
6 Dialysate calcium concentrations Ca dialysate 1.5 mmol/l Neutral Ca balance** Ca dialysate 1.75 mmol/l Positive Ca balance** Ca dialysate 1.25 mmol/l Negative Ca balance**..however, Ca transfer during dialysis depends also on the Ca gradient between serum and dialysate concentration and total calcium balance as well on vitamin D and Ca binder use Toussaint et al. Hemodial Int 2006
7 Dialysate calcium concentrations acute effects Hemodynamic stability on dialysis Intradialytic hypotension Preventive effect of high dca (1.75mmol/l) Increased cardiac contractility (+ increased peripheral resistence) synergistic effect with high dmg and high dhco 3 Maynard et al. Ann Intern Med 1986 Heinrich et al. NEJM 1984 Gabutti et al. NDT 2009 Gabutti et al. NDT 2009 Toussaint et al. Hemodila Int 2006
8 Dialysate calcium concentrations acute effects Hemodynamic stability on dialysis Calcium overload with chronic dca 1.75mmol/l?? dca profiling (n=18) dca 1.25 for 4h vs dca 1.25 for 2h then 1.75 for 2h vs dca 1.5 for 4h n=8 9 treatments with 1.25 vs 9 with 1.25/1.75 dca in random order Reduced intradialytic events Kyriazis et al. Kidney Int 2002
9 Dialysate calcium concentrations acute effects Cardiac arrhythmias N= HD patients, N=510 witnessed cardiac arrest vs 1560 matched controls Risk probably potentiated with concomitant hypokaliemia (or large dialysate serum K + gradient) Pun et al. CJASN 2013 Severi et al. NDT 2008
10 Dialysate calcium concentrations chronic effects Effects on bone Low turn over bone disease PTH (!) Reduction of dca from 1.75 to 1.25 mmol/l or from 1.5 to 1.25mmol/l PTH (+ others) Fiedler et al. Nephron Clin Pract 2004 Hamano et al. Bone 2005 High turn over bone disease Suppression of PTH with higher dca (1.75 mmol/l) Toussaint et al. Hemodial Int 2006
11 Dialysate calcium concentrations chronic effects Effects on vessels? Higher dca aortic puls wave velocity (=vascular stiffness) over time (6 mts) Hypercalciemia..however Acute effects of dca variations on PWV observed LeBoeuf et al. NDT 2011 Charitaki et al. BMC Nephrology 2013 LeBoeuf et al. NDT 2011 Kim et al. Korean J Int Med 2011 Davenport et al. Blood Purif 2010 vascular stiffness = vascular calcification??
12 Summary dialysate calcium concentrations Dialysate Calcium Advantages Disadvantages Low ( mmol/l) Risk for Hypercalciemia Potential for negative Ca balance and PTH Greater use of Vitamin D and Ca containing phosphate binders allowed Intra dialytic hypotension Benefit in adynamic bones Cardiac arrhythmias High ( mmol/l) hemodynamic stability Risk of hypercalciemia Benefit on bone protection in nocturnal HD Limited use of vitamin D and calcium based binders PTH Risk of vascular calcification adapted from Toussaint et al. Hemodial Int 2006
13 Dialysate magnesium Magnesium in ESRD Vascular tone ( ) Heart contractility ( ) Arrhythmias ( ) LV Hypertrophy ( ) PTH ( ) Osteoporosis ( ) Insulin Resistance ( ) Inflammation ( ) Vascular calcification ( ) Mortality ( )
14 Dialysate Magnesium: Mg kinetics during high efficiency dialysis HD Session with 0 mmol/l Mg removal 486 +/ 44mg HD Session with 0.25 mmol/l Mg removal 306 +/ 69 mg HD Session with 0.75 mmol/l Mg removal 56 +/ 50m Plasma Mg concentrations constant with 0.75mmol/l
15 Dialysate Magnesium: acute effects Blood pressure and myocardial contractility n=8, in randomized order, 4 h HD Group I Mg 0.75, Ca 1.75 Group II Mg 0.25, Ca 1.75 Group III Mg 0.75, Ca 1.25 Group IV Mg 0.25, Ca 1.25 Group I and III: smg +2% Low Ca, low Mg Group II and IV:s Mg 35% Group IV: CI, stroke Index, MAP Kyriazis et al. Kidney Int 2004
16 Dialysate Magnesium: acute effects Blood pressure and myocardial contractility n=14 (ca 1.25mmol/l) 4 weeks with 0.5mmol/l 4 weeks with 0.25 mmol/l 4 weeks with 0.75 mmol/l dmg 0.75mmol/l significant reduction in intradialytic morbidity and improved BD stability Intradialytic changes of serum Mg correlation with hypotensive episodes Elsharkawy et al. Hemodial Int 2006 Kyriazis et al. Kidney Int 2004
17 Dialysate magnesium: acute effects Muscle cramps n=15 Switch from 0.75 to 0 mmol/l dmg + oral MgCO 3 for 2 weeks and dmg 0.25 mmol/l for 2 weeks Severe muscle cramps (n=8) not associated with changes in blood pressure Immediate relief after switch to 0.75 mmol/l and dmg oral Mg CO 3 mmol/l for 2 weeks Well tolerated Kelber et al. AJKD 1994
18 Dialysate magnesium: which one to choose? Optimal dmg concentration 0.75 mmol/l for blood pressure and muscle cramps (...if no Mg phosphate binder is used) Information from guidelines? EBPG on HD (2007) in patients with frequent episodes of IHD, low (0.25mmol/l) dmg should be avoided, especially in in combination with low calcium dialysate CARI (2000) mmol/l will maintain normomagnesemia...but levels in some case may have to be individualised
19 Dialysate magnesium: chronic effects Evidence from animal studies supporting use of higher dmg Mg supplemented diet prevents/retards VC Gorgels et al. J Mol Med 2010 Mg CO3 phosphate binder vs Lanthanum prevents VC Li et al. Clin Transl Sci 2009 by unclear, probably multiple mechanisms (direct inhibition of hydroxyapatite formation, cellular effects, expression of anti calcification proteins...) Massy et al. Clin Kidney J 2012
20 Dialysate Magnesium: chronic effects Evidence from human studies supporting the use of higher dmg Tissue calcification Low serum Mg in HD patients vascular calcification (VC) (independent of Ca, Ph, and PTH) Ishimura et al. Clin Nephrol 2007 Mitral annular calcifications Tzanakis et al. NDT 1997 Increased carotid intima media thickness oral Mg supplementation reduces thickness Turgut et al. Int Urol Nephrol 2008 Dietary Mg (MgCO 3 / Mg citrate) supplementation prevents/retards (VC) Turgut et al. Int Urol Nephrol 2008 Spiegel et al. Hemodial Int 2009
21 Dialysate magnesium: chronic effects Evidence from human studies supporting the use of higher dmg Outcome n= 515 HD patients, mean follow up 51 months, observational prospective Higher Mg group >1.1.4mmol/l Lower Mg group < 1.14mmol/l Serum Mg at 0 and 1 year correlates strongly Serum Mg = independent significant predictor overall mortality (OR 0.48 per 0.41 mmol/l Mg) Ishimura et al. Magnes Res 2007
22 Dialysate magnesium: chronic effects Evidence from human studies supporting the use of higher dmg Outcome n= (FMC North America facilities) retrospecitve Results Compared to mid normal values ( mmol/l) drop of hazard ratio at smg 0.95 mmol/l to as low as 0.68 at smg > 1.15 mmol/l Linear trend lower mortality with increasing serum Mg concentrations Lacson et al. Poster at the Renal Week 2009 in San Diego, US Passlick Deetjen, oral presentation at the ERA/EDTA Congress 2012 in Munich, Germany
23 Dialysate magnesium: chronic effects Evidence from human studies supportin the use of higher dmg Effects on serum calcification propensity JASN 2012 N =45 chronic HD patients, crossover design Assessment of calcification propensity with a 0.5mmol/l dmg vs 0.75mmol/l dmg JASN 2013 Preliminary Results 0.75mmol/l dmg improves calcification propensity in serum of HD Patients under preparation for publication Effect on outcome?
24 Dialysate calcium: Summary Optimal dca concentration Guidelines (KDOQI): mmol/l Compromise between the need for personal suggestion (after review of literature) cardiovascular stability during HD the goal to maintain normal (?) bone turnover and tissue mineralization
25 Dialysate magnesium: Summary Optimal dmg concentration No or few comments in major guidelines dmg 0.75 (or higher?) favorable for personal suggestion (after review of literature) cardiovascular stability during dialysis probable positive effect on vascular calcification no major side effects reported (without concomitant use of Mgphosphate binders)
2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationTO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT?
TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT? Rana G. Rizk, PhD, MPH, LD Maastricht University, The Netherlands November, 2017 Learning objectives Review the evidence behind benefits and concerns
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationIpovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano
Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationKDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke
CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke Unité 1088 de l Inserm UFR de Médecine et de Pharmacie Jules Verne University of Picardie Amiens, France Poten2al conflicts of interest Research support:
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationLa relation dialyse et nutrition
Nutrition en dialyse : controverses La relation dialyse et nutrition Charles Chazot, MD NephroCare Tassin-Charcot Sainte Foy Les Lyon, France HEMO study lessons (1) Dose Body weight flux Rocco, Kidney
More informationIMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia
IMPLEMENTATION OF THE CKD-MBD GUIDELINES Introduction INTO CLINICAL to Renagel PRACTICE Goce Spasovski, R. Macedonia Antalya, Turkey, September 16 2012 Session Objectives Guidelines needs and controversy
More informationThe goal of dialysis for patients with chronic renal failure is to
Dialysate Composition in Hemodialysis and Peritoneal Dialysis Biff F. Palmer The goal of dialysis for patients with chronic renal failure is to restore the composition of the body s fluid environment toward
More informationTiming, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement
Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Prof. Dr. Achim Jörres Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
More informationTreatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD
More informationTHE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION
THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory
More informationHemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK
Hemodiafiltration: principles and advantages over conventional HD Rukshana Shroff Great Ormond Street Hospital for Children London, UK Effectiveness of RRT modalities Mcfarlane, Seminars in dialysis, 2009
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationHEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW
HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS This document was prepared at the request of the BC Hemodialysis Committee to provide a brief overview of the literature and to identify
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationLevel 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor
chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationCa, Phos and Vitamin D Metabolism in Pre-Dialysis Patients
Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man
More informationCardiovascular Complications of Dialysis In Children. Why is this important? Why is this Important? 01/26/2017. Dr Daljit Hothi
Cardiovascular Complications of Dialysis In Children Dr Daljit Hothi Great Ormond Street Hospital, London Why is this important? 100 90 Why is this Important? Long Term Survival of Childhood Onset ESRD
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationManagement of CKD. Goce Spasovski, R. Macedonia
Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationKDOQI Guidelines. Overview. Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium
DISCLOSURES: NONE Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium KDOQI Guidelines AV fistulas have better outcomes than grafts or catheters
More informationEffects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients
DIALYSIS Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients Ahmed Alayoud, 1 Driss El Kabbaj, 2 Mohammed Benyahia, 2 Mohammed
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationSetting the standard
SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationKDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE
LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE Dr. Christopher T Chan Director Division of Nephrology University Health Network Professor of Medicine University of Toronto Disclosure
More informationCalcium Management for Patients Receiving Extended Duration Hemodialysis
Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1
More informationLife Science Journal 2014;11(10)
Comparison between two dialysate calcium concentrations on parathormone level in hemodialysis patients with and without valvular calcification Dawlat Belal 1, Bahaa Zayed 1, Eglal Kenawy 2, Malak Nabil
More informationMacro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease. T. Alp Ikizler, MD Vanderbilt University Medical Center
Macro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease T. Alp Ikizler, MD Vanderbilt University Medical Center Nutrition and Chronic Kidney Disease What is the disease itself and
More informationCalcimimetic agents, vascular calcification prevention 276 Calcium parathyroid hormone regulation Subject Index 357
Subject Index Advanced glycation end products (AGEs) atherosclerosis role 168 dietary sources 202, 203 formation 168 platelet phosphatidylserine externalization induction 171, 172 signaling 173 toxicity
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationStructural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak
Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak Kerstin Amann Nephropathology, Dept. of Pathology, University of Erlangen-Nürnberg Krankenhausstr. 8-10 91054
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationSodium elimination and dialysate sodium. How much? Does it matter?
Sodium elimination and dialysate sodium How much? Does it matter? A. Bock Nephrologie Dialysis visit Aarau 3.12.2013 90 kg dialysis patient: 5 kg over dry weight Recent dyspnea. Minimal leg edema RBV in
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationA new era in phosphate binder therapy: What are the options?
http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School
More informationCKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism
CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:
More informationMaher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University
Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN
More informationPREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL
PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL ADEJUMO OA, OLOKOR AB, IYAWE IO, OKAKA EI, UNUIGBE EI, OJOGWU LI Presented at Nigerian
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationDialysis: the long case
Dialysis: the long case Prof Mark Brown St George Public Hospital, Kogarah The case SD 1. What significant things have been omitted from the history? 2. Physical findings 70 RTA; mitral regurg murmur;
More informationUse of magnesium as a drug in chronic kidney disease
Clin Kidney J (2012) 5[Suppl 1]: i62 i70 doi: 10.1093/ndtplus/sfr168 Use of magnesium as a drug in chronic kidney disease Alastair J. Hutchison 1 and Martin Wilkie 2 1 University of Manchester and Manchester
More informationAchieving Equilibrium in ESRD Patients
Achieving Equilibrium in ESRD Patients -Marc Richards MD -South Florida Kidney Disease and HTN Specialists -Chief of Medicine, BRRH -BRRH Grand Rounds: April 18 th, 2017 Outline Dialysis prescription Adequacy
More informationOn Referral to our Unit
Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationSecondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationNutrition and Renal Disease Update
Nutrition and Renal Disease Update Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France What have we learned? 1. Chronic kidney disease:
More informationEpidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis
Epidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis Pr Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France ESRD
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationHemodynamic Instability in HD patients: Dialysis Hypotension Prof Ali BAŞÇI MD FERA Ege University Medical School
Hemodynamic Instability in HD patients: Dialysis Hypotension Prof Ali BAŞÇI MD FERA Ege University Medical School Relationship between blood pressure and mortality in patients treated with volume control
More informationOutline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010
Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,
More informationPr Denis FOUQUE. Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France
Pr Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France Observatoire Phosphocalcique, January 2011 1200 36.1 ± 5.0 g/l 1050 900 PEW
More informationStefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.
Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece Passive, degenerative accumulation process of Ca ++ /P +++ without treatment options Active, complex, condition:
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationResearch Article Magnesium and Muscle Cramps in End Stage Renal Disease Patients on Chronic Hemodialysis
Advances in Nephrology, Article ID 681969, 6 pages http://dx.doi.org/10.1155/2014/681969 Research Article Magnesium and Muscle Cramps in End Stage Renal Disease Patients on Chronic Hemodialysis Patrick
More informationTherapeutic Challenges in CKD & ESRD: Managing Acid-base & electrolytes. No financial disclosure
Therapeutic Challenges in CKD & ESRD: Managing Acid-base & electrolytes Qi Qian, MD, FASN Mayo Clinic, College of Medicine No financial disclosure 2016 MFMER 3563115-1 ü - ü - 1. Acidosis 2. Hyperkalemia
More informationThe Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD
The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationInvestigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis
Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Tutorial for Specialist Portfolio Biomedical Scientists 03/02/2014 Dr Petros Kampanis Clinical Scientist 1. Calcium Most abundant
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationDrugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia
NSW Therapeutic Advisory Group Level 5, 376 Victoria Street PO Box 766 Darlinghurst NSW 2010 Phone: 61 2 8382 2852 Fax: 61 2 8382 3529 Email: nswtag@stvincents.com.au www.nswtag.org.au Drugs for the treatment
More informationParsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1
Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationA team s approach to QOL in CKD patients
A team s approach to QOL in CKD patients Edwin Fong MD FRCPC Which Team? Beauty Symmetry Beauty defined Suntanned Narrower face Less fat Fuller lips Bigger distance of eyes Darker eye brows Higher cheek
More informationDialysis in frail and Elderly
Dialysis in frail and Elderly Dr Shibu Jacob, Assistant Professor, Christian Medical College, Vellore. ISHDCON April 2,2017 Complications during dialysis and soon after? How to minimise these? Should
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationCARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017
CARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017 RENEGOTIATING LIFE WITH CHRONIC KIDNEY DISEASE CONSTANTINI
More informationDo higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse wave velocity?
Charitaki and Davenport BMC Nephrology 2013, 14:189 RESEARCH ARTICLE Open Access Do higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse
More informationControl of hyperphosphatemia is a major goal in patients
ORIGINAL ARTICLES Phosphorus Clearance Using Two Hemodialyzers Placed in Parallel Mitchell H. Rosner, 1,2 Allen Helmandollar, 1 Ryan Evans, 1 Emaad Abdel-Rahman 1 Division of Nephrology, 1 University of
More informationEnd stage renal disease and Protein Energy wasting
End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationPediatric CKD-MBD: pathophysiology and management
Pediatric CKD-MBD: pathophysiology and management Justine Bacchetta, MD, PhD Reference Center for Rare Renal Diseases Reference Center for Rare Diseases of Calcium and Phosphate Bron, France Overview of
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More information